Ram Aiyar, Korro CEO

Can RNA edit­ing take At­las start­up where Ver­tex could­n't go? Ko­r­ro lands $116M to find out

As the CEO of RNA edit­ing start­up Ko­r­ro Bio, Ram Ai­yar of­ten gets the same ques­tion.

“I get al­ways asked, you know, if you can fix DNA, why both­er with RNA?” he told End­points News. “And it’s like ask­ing, which child do you pre­fer — your old­er one or your younger one?”

But in­vestors are ap­pre­ci­at­ing the dif­fer­ence. More than a year af­ter clos­ing its Se­ries A just shy of the megaround mark, Ko­r­ro Bio is back in the spot­light with $116 mil­lion in fresh cash and a lead can­di­date — tar­get­ing al­pha-1 an­tit­rypsin de­fi­cien­cy, or AATD.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.